Taysha Gene Therapies (TSHA) reported Q2 net loss late Tuesday of $0.13 per diluted share, compared with a loss of $0.09 per diluted share a year earlier.
Analysts polled by FactSet expected a loss of $0.11.
The company reported no revenue for the quarter ended June 30, compared with about $2 million a year earlier.
Analysts polled by FactSet expected $700,000.
As of June 30, the company said it had cash and cash equivalents of $455.4 million, expected to fund operating expenses and capital requirements through H2 of 2028.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.